| 1.92 0.05 (2.67%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.46  |
1-year : | 4.38 |
| Resists | First : | 2.96 |
Second : | 3.75 |
| Pivot price | 2.01 |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 1.9 |
MA(20) : | 2.22 |
| MA(100) : | 4.49 |
MA(250) : | 6.63 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 16 |
D(3) : | 11.9 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 40.79 | Low : | 1.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BJDX ] has closed above bottom band by 42.6%. Bollinger Bands are 80.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.05 - 2.06 | 2.06 - 2.07 |
| Low: | 1.74 - 1.75 | 1.75 - 1.76 |
| Close: | 1.95 - 1.97 | 1.97 - 1.98 |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Fri, 06 Mar 2026
Bluejay 10-K: Net loss $6.85M, operating loss $6.95M; cash through Q3 2026 - TradingView
Fri, 06 Mar 2026
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook - The Manila Times
Fri, 06 Mar 2026
Bluejay’s 20-minute sepsis test drives 2026 plan and $20M cash goal - Stock Titan
Fri, 20 Feb 2026
Bluejay Diagnostics Announces Full Exercise of Prefunded Warrants and Current Share Structure Update - Quiver Quantitative
Tue, 17 Feb 2026
Sepsis test maker builds supply for 10M rapid kits as key trial advances - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | 657.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.1 % |
| Return on Equity (ttm) | -117.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|